GlassScriptPhysician profile
Peaches Duon
NPI 1326622788
$1,475.66
in general payments reported to CMS, 2019-2025
20 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.40 · 2022: $15.70 · 2023: $114 · 2024: $149 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.92 | 2025 | |
| Lilly USA, LLC | $145.14 | 2025 | Zepbound, Jardiance, Mounjaro |
| Lucid Diagnostics INC. | $120.56 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $100.24 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.47 | 2025 | Caplyta |
| Amgen INC. | $91.65 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $88.39 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Myriad Women'S Health, INC. | $80.35 | 2023 | Myrisk |
| Exact Sciences Corporation | $53.39 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $52.29 | 2023-2025 | Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $46.05 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.52 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $28.65 | 2025 | |
| Pfizer INC. | $24.54 | 2025 | |
| Corcept Therapeutics | $23.33 | 2025 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $22.94 | 2025 | Nexletol |
| Radius Health, INC. | $20.70 | 2025 | Tymlos |
| Dexcom, INC. | $20.29 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $16.40 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.84 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peaches Duon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.